Full bill text rendering is coming soon.
In the meantime, read the full text on Congress.gov ↗.
Regulatory or Legal Changes Top 3
FDA Clinical Trial Status Review for Grant Renewals
Requires the Food and Drug Administration (FDA) to assess clinical trial enrollment data when reviewing grant renewal applications and to request interim clinical trial data from manufacturers of investigational ALS drugs as part of that review process.
- Population Scope Low Directly affects only manufacturers of investigational ALS drugs seeking grant renewals — a very small set of regulated entities.
- Budgetary Magnitude Low No funds are authorized or appropriated; the provision imposes procedural obligations within the existing grant review framework.
- Legal / Regulatory Depth Medium Creates new mandatory procedural duties on the Food and Drug Administration (FDA) — enrollment-status assessment and interim-data requests — that constrain agency conduct during grant renewals without altering substantive eligibility law.
- Degree of Discretion Granted Low Both duties use 'shall,' leaving FDA no discretion over whether to assess enrollment status or request interim data.
- Implementation & Enforcement Burden Low Adds a recurring administrative review step for FDA but creates no new enforcement mechanism, penalty, or compliance infrastructure.
- Temporal Commitment High Enacted as a permanent statutory amendment with no expiration, so it binds FDA indefinitely unless Congress acts to repeal it.
No signal yet
Core Policy Mechanism Top 3
FDA ALS Action Plan Report Requirement
Requires the Commissioner of Food and Drugs to publish within one year a report on the FDA website containing an updated five-year action plan for ALS and rare neurodegenerative disease therapy development and a retrospective assessment of the 2022 FDA Action Plan for Rare Neurodegenerative Diseases.
- Population Scope Low Directly affects the Food and Drug Administration (FDA) as the obligated actor; benefits accrue to ALS and rare neurodegenerative disease communities, a small share of the U.S. population.
- Budgetary Magnitude Low No funds are authorized or appropriated; the provision requires only a reporting and planning activity by FDA.
- Legal / Regulatory Depth Medium Creates a one-time mandatory reporting obligation on FDA Commissioner with specific content requirements, a procedural statutory duty rather than a change to substantive regulatory authority.
- Degree of Discretion Granted Low The 'shall publish' mandate and enumerated content requirements leave FDA no discretion over whether to produce the report or what categories it must cover.
- Implementation & Enforcement Burden Low Requires a single report publication with no new enforcement mechanism, penalty, or ongoing compliance obligation.
- Temporal Commitment High Enacted as a permanent statutory amendment with no expiration; the obligation persists indefinitely even after the one-time report is filed, binding future Commissioners unless Congress repeals it.
No signal yet
Duration, Sunset, and Review Top 3
ALS Act Reauthorization Through FY2031
Extends the authorization of the Accelerating Access to Critical Therapies for ALS Act and its associated grant program for ALS research from fiscal year 2026 through fiscal year 2031, keeping the program's legal authority active for an additional five years.
- Population Scope Low ALS patients, researchers, and grant recipients are a small, specialized population representing a fraction of a percent of the U.S. population.
- Budgetary Magnitude Medium Extends the authorization to appropriate grant funds through FY2031, a five-year continuation of a recurring discretionary program — meaningful in duration but not quantified at a large dollar scale in the bill text.
- Legal / Regulatory Depth Medium Extending a sunset date preserves existing statutory authority rather than creating new substantive law, a procedural-temporal change that keeps the program's legal framework in force.
- Degree of Discretion Granted Medium Preserves the existing grant-award discretion Food and Drug Administration (FDA) already held under the original Act, neither expanding nor constraining that authority.
- Implementation & Enforcement Burden Low Continuing an existing program adds no new enforcement mechanisms or compliance requirements beyond what was already operative.
- Temporal Commitment Low The authorization expires at the end of FY2031 — a hard expiry within ten years — so it self-terminates unless Congress acts to extend it again.
No signal yet
No possible riders have been surfaced for this bill.
Summary
This bill reauthorizes the Accelerating Access to Critical Therapies for ALS Act (Public Law 117-79) through fiscal year 2031, extending both the general program and the grant funding authorization from 2026 to 2031. It also adds new procedural requirements for the Food and Drug Administration (FDA) to assess clinical trial enrollment status and request interim trial data when reviewing grant renewal applications, clarifies the definition of 'phase 3' clinical trials, requires FDA Commissioner to publish an updated action plan and retrospective report on rare neurodegenerative disease initiatives within one year, and directs the Government Accountability Office (GAO) to submit a report to Congress within four years.
AI-generated summary, pending human review.
| Version | Event | Date | User support | Your vote | Roll calls |
|---|---|---|---|---|---|
| Original |
Initial publication
Apr 6, 2026
|
Apr 6, 2026 | No votes yet | — | — |
Log in or create an account to record your vote on this legislation. Results are visible to all visitors.
Regulatory or Legal Changes Top 3
FDA Clinical Trial Status Review for Grant Renewals
Requires the Food and Drug Administration (FDA) to assess clinical trial enrollment data when reviewing grant renewal applications and to request interim clinical trial data from manufacturers of investigational ALS drugs as part of that review process.
- Population Scope Low Directly affects only manufacturers of investigational ALS drugs seeking grant renewals — a very small set of regulated entities.
- Budgetary Magnitude Low No funds are authorized or appropriated; the provision imposes procedural obligations within the existing grant review framework.
- Legal / Regulatory Depth Medium Creates new mandatory procedural duties on the Food and Drug Administration (FDA) — enrollment-status assessment and interim-data requests — that constrain agency conduct during grant renewals without altering substantive eligibility law.
- Degree of Discretion Granted Low Both duties use 'shall,' leaving FDA no discretion over whether to assess enrollment status or request interim data.
- Implementation & Enforcement Burden Low Adds a recurring administrative review step for FDA but creates no new enforcement mechanism, penalty, or compliance infrastructure.
- Temporal Commitment High Enacted as a permanent statutory amendment with no expiration, so it binds FDA indefinitely unless Congress acts to repeal it.
No signal yet
Regulatory or Legal Changes
FDA Clinical Trial Status Review for Grant Renewals
Core Policy Mechanism Top 3
FDA ALS Action Plan Report Requirement
Requires the Commissioner of Food and Drugs to publish within one year a report on the FDA website containing an updated five-year action plan for ALS and rare neurodegenerative disease therapy development and a retrospective assessment of the 2022 FDA Action Plan for Rare Neurodegenerative Diseases.
- Population Scope Low Directly affects the Food and Drug Administration (FDA) as the obligated actor; benefits accrue to ALS and rare neurodegenerative disease communities, a small share of the U.S. population.
- Budgetary Magnitude Low No funds are authorized or appropriated; the provision requires only a reporting and planning activity by FDA.
- Legal / Regulatory Depth Medium Creates a one-time mandatory reporting obligation on FDA Commissioner with specific content requirements, a procedural statutory duty rather than a change to substantive regulatory authority.
- Degree of Discretion Granted Low The 'shall publish' mandate and enumerated content requirements leave FDA no discretion over whether to produce the report or what categories it must cover.
- Implementation & Enforcement Burden Low Requires a single report publication with no new enforcement mechanism, penalty, or ongoing compliance obligation.
- Temporal Commitment High Enacted as a permanent statutory amendment with no expiration; the obligation persists indefinitely even after the one-time report is filed, binding future Commissioners unless Congress repeals it.
No signal yet
Core Policy Mechanism
FDA ALS Action Plan Report Requirement
Duration, Sunset, and Review Top 3
ALS Act Reauthorization Through FY2031
Extends the authorization of the Accelerating Access to Critical Therapies for ALS Act and its associated grant program for ALS research from fiscal year 2026 through fiscal year 2031, keeping the program's legal authority active for an additional five years.
- Population Scope Low ALS patients, researchers, and grant recipients are a small, specialized population representing a fraction of a percent of the U.S. population.
- Budgetary Magnitude Medium Extends the authorization to appropriate grant funds through FY2031, a five-year continuation of a recurring discretionary program — meaningful in duration but not quantified at a large dollar scale in the bill text.
- Legal / Regulatory Depth Medium Extending a sunset date preserves existing statutory authority rather than creating new substantive law, a procedural-temporal change that keeps the program's legal framework in force.
- Degree of Discretion Granted Medium Preserves the existing grant-award discretion Food and Drug Administration (FDA) already held under the original Act, neither expanding nor constraining that authority.
- Implementation & Enforcement Burden Low Continuing an existing program adds no new enforcement mechanisms or compliance requirements beyond what was already operative.
- Temporal Commitment Low The authorization expires at the end of FY2031 — a hard expiry within ten years — so it self-terminates unless Congress acts to extend it again.
No signal yet
Duration, Sunset, and Review
ALS Act Reauthorization Through FY2031
Incomplete vote
You have not made a selection on all required items:
Choose Neutral if you prefer not to commit. Leaving without completing will remove all your votes for this bill from the totals.
Maximum recommendations reached
You have already recommended the maximum number of components allowed on this bill. To recommend [new component], choose one of your current recommendations to unselect: